

# Total Synthesis of Crotomachlin

Denyse Herlem, Françoise Khuong-Huu\*


CNRS, Institut de Chimie des Substances Naturelles, 91190 Gif-sur-Yvette, France.

Andrew S. Kende

University of Rochester, Department of Chemistry, Rochester, N.Y. 14627, USA

**Abstract-** The synthesis of the racemic  $6\beta$ ,  $7\beta$ ,  $8\alpha$ -trihydroxy labdadiene, **1** was achieved starting from decalin **3**. Diene **1** was found to be identical to crotomachlin, a diterpene from *Croton macrostachys*, in which the configuration at C-8 has not been established with certainty.


In a previous paper,<sup>1</sup> we described the reactions required to introduce a diene side chain and hydroxyl substituents on a substituted decalin prepared from geraniol and  $\beta$ -ionone. We now report the first total synthesis of racemic diene **1**, thereby establishing the complete stereochemistry of the diterpene crotomachlin product isolated from *Croton macrostachys*<sup>2</sup> found to be identical with  $6\beta$ ,  $7\beta$ -dihydroxy-12E-abienol isolated by Bohlmann and *al.*<sup>3</sup> from *Koanophyllon conglobatum*.<sup>4</sup> This compound shows antilipoxygenase activity *in vitro*.



To minimize neighbouring-group side reactions such as those previously encountered, we chose to investigate functionalization of the octalones **8** or **10**, both accessible (Scheme 1) from the previously described dioxolane aldehyde **3**.<sup>1</sup>

Reduction of aldehyde **3** with  $\text{NaBH}_4$ , followed by dioxolane cleavage gave carbinol **5**, mp 76–77°C, which was protected as the *t*-butyldimethylsilyl ether **6**. Introduction of the 6,7-alkene by  $\text{Pd}(\text{OAc})_2$  oxidation of enol silane **7**,<sup>5</sup> followed by stereospecific  $\text{MeLi}$  addition, gave carbinol **9**. Oxidative transposition with  $\text{PCC}$ <sup>6</sup> produced enone **10**, mp 60°C, in 92% yield.<sup>7</sup>

Scheme 1



a)  $\text{NaBH}_4$ , 2 eq, EtOH, rt, 98%; b) 1N HCl, THF/ $\text{H}_2\text{O}$ , rt, 82%; c) TBDMSCl, 1.2 eq., imidazole 2 eq, THF, rt, overnight, 95%; d) LDA, 5 eq, THF, -78°C, 1h, then  $\text{ClSiMe}_3$ , 2 eq, -78°C to 0°C, 72%; e)  $\text{Pd}(\text{OAc})_2$ , 1.2eq, MeCN, rt, overnight, 85%; f)  $\text{MeLi}$ , 2 eq., ether, 0°C, 1 h, 98%; g)  $\text{PCC}$ , 4.5eq., NaOAc,  $\text{CH}_2\text{Cl}_2$ , 0°C, 15 min, then, rt, 2 h, 91%.


Our strategy was to fully elaborate the 6 $\beta$ ,7 $\beta$ ,8 $\alpha$ -triol functionality in the B-ring of **10** prior to the construction of the diene side chain, as in Scheme 2.

To this end, catalytic  $\text{OsO}_4$ -NMO<sup>8</sup> oxidation of **10** gave the diol **11**, mp 95°C. To ascertain the stereochemistry of the *cis* diol **11**, 2D nuclear Overhauser experiments were carried out with triol **12**, mp 144–145°C, in which the methyl signals of the proton NMR were well separated. NOE effects were observed between the C(20)-Me and the C(17)-Me, and also between the C(20)-Me and the C(19)-Me, showing that the *cis*-hydroxylation reaction had occurred, as anticipated, on the less hindered  $\alpha$ -side of the molecule.

Acetylation of triol **12** with  $\text{Ac}_2\text{O}$ -py gave diacetate **13**, mp 134–135°C, from which the tertiary alcohol was protected as ethoxyethyl ethers **14** present as the mixture of ethoxyethyl epimers. Cleavage of the acetates with 2% KCN in MeOH<sup>8</sup> gave ketol **15**. Selective silylation of the primary hydroxyl now produced **16** which on Dess-Martin oxidation<sup>10</sup> gave dione **17**. Reduction of this dione **17** with excess  $\text{NaBH}_4$  in EtOH provided the 6 $\beta$ ,7 $\beta$ -diol **18** which was then reacted with one equivalent of  $\text{COCl}_2$  in PhMe in the presence of pyridine to give the cyclic carbonate **19**.<sup>11</sup> Desilylation of the primary alcohol with *n*- $\text{Bu}_4\text{NF}$  gave the key intermediate **20**.


Our synthesis was completed by side chain elaboration from the aldehyde **21**, prepared in high yield by Dess-Martin oxidation<sup>10</sup> of carbinol **20** (Scheme 3). A Horner-Emmons condensation of **21** with the sodio derivative of ethyl 2-diethylphosphonopropionate in PhMe gave the *E*-olefin **22** as major product (*E/Z*>95/5). Reduction of the ester function with  $\text{LiAlH}_4$  was accompanied by carbonate cleavage to provide triol **23**.

Scheme 2



a)  $\text{OsO}_4$ , catalytic, NMO, 3 eq., *t*-BuOH, acetone,  $\text{H}_2\text{O}$ , rt, 48 h, 55%; b) TBAF, 1 eq., THF, rt, 3 h, 90%; c)  $\text{Ac}_2\text{O}$ , excess, py, rt, overnight, 86%; d) ethylvinyl ether, 5 eq., CSA, catalytic,  $\text{CH}_2\text{Cl}_2$ , overnight, 70%; e) 2 % KCN, MeOH, overnight, 91%; f) TBDMSCl, 1.2 eq., imidazole, 3 eq., THF, rt, overnight, 96%; g) Dess-Martin periodinane, 1 eq.,  $\text{CH}_2\text{Cl}_2$ , rt, 1 h, 90%; h)  $\text{NaBH}_4$ , 5 eq., EtOH, rt, overnight, 64%; i)  $\text{COCl}_2$ , 1.2 eq., toluene, py, rt, overnight, 92%; j) TBAF, 1 eq., THF, rt, 3 h, 91%.

Scheme 3



a) Dess-Martin periodinane, 1 eq.,  $\text{CH}_2\text{Cl}_2$ , rt, 1 h, 90%; b) ethyl 2-diethylphosphonopropionate, 3 eq., NaH, 3 eq., toluene,  $80^\circ\text{C}$ , 1 h, 56%; c)  $\text{LiAlH}_4$ , 2 eq., ether, rt, 3 h, 70%; d) Dess-Martin periodinane, 1 eq.,  $\text{CH}_2\text{Cl}_2$ , rt, 1 h, 92%; e)  $\text{H}_2\text{C}=\text{PPh}_3$ , 5 eq., THF,  $0^\circ\text{C}$ , 3 h, 51%; f) PPTs, catalytic, MeOH, rt, 30 min., 98%.

The allylic primary alcohol was selectively oxidised with one equivalent of Dess-Martin periodinane to give aldehyde **24**. Wittig reaction with excess methylenetriphenylphosphorane converted **24** to **25**. Mild hydrolysis of the ethoxyethyl protecting group with PPTS in MeOH, provided pure racemic triol diene **1**.

The spectroscopic data ( $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$ , UV, MS)<sup>12</sup> obtained for synthetic ( $\pm$ )-**1** were identical to those described for crotomachlin<sup>2</sup> and 6 $\beta$ ,7 $\beta$ -dihydroxy-12E-abienol.<sup>3</sup> The present work thus unambiguously establishes the 6 $\beta$ ,7 $\beta$ ,8 $\alpha$ -triol stereochemistry in this natural product.

**Acknowledgements-** The authors thank the Mass Spectrometry Laboratory of the Institut de Chimie des Substances Naturelles for the high resolution CIMS determinations and Professor Pierre Potier for his encouragement. Partial support of this research by grant CA-18846, awarded to A.S.K. by the National Cancer Institute (NIH, USPHS) is gratefully acknowledged.

### References and Notes

- Herlem, D.; Kervagoret, J.; Dahai, Y.; Khuong-Huu, F.; Kende, A.S.; *Tetrahedron*, **1993**, *49*, 607-618.
- Personal communication from Professor Isao Kubo (UC Berkeley). We are grateful to Professor Kubo for providing us reference spectra of crotomachlin prior to publication.
- Bohlmann, F.; Scheidges, C.; King, R.M.; Robinson, H. *Phytochemistry*, **1984**, *23*, 1190-1192.
- Professor S. Isoe (Osaka City University) has recently communicated to us that his group has synthesized 8 $\beta$ -epicrotomachlin having a C(8) $\beta$ -hydroxyl, thereby independently concluding that crotomachlin has the C(8) $\alpha$ -configuration.
- Ito, Y.; Hirao, T.; Saegusa, T. *J. Org. Chem.* **1978**, *43*, 1011-1013.
- Dauben, W.G.; Michno, D.M. *J. Org. Chem.* **1977**, *42*, 682-685.
- Enone **10**:  $\text{C}_{22}\text{H}_{40}\text{O}_2\text{Si}$ , Calc. %: C 72.47, H 11.06, found C 72.27, H 10.83; MS, CI:  $\text{MH}^+$  365,  $m/z$  361, 313, 257; IR  $\text{cm}^{-1}$ : 1682 ( $\nu_{\text{C=O}}$ ), 1635 ( $\text{C=C}$ ), 1100 ( $\text{C-O}$ ); UV  $\lambda_{\text{max}}$  EtOH: 238 nm,  $\epsilon$  11 617;  $^1\text{H}$  NMR, 250 MHz,  $\delta$  ppm: 0.06 (6H, s, 2 SiCH<sub>3</sub>), 0.83 (3H, s, C-20H<sub>3</sub>), 0.90 (9H, s, tBu), 1.11 (3H, s, C-19H<sub>3</sub>), 1.16 (3H, s, C-18H<sub>3</sub>), 1.90 (3H, s, C-17H<sub>3</sub>), 1.0-2.2 (9 H, m, CH, CH<sub>2</sub>), 2.05 (1H, s, C-5H), 3.66 and 3.73 (2H, 2m, CH<sub>2</sub>-12), 5.73 (1H, q, J=1, H-7);  $^{13}\text{C}$  NMR,  $\delta$  ppm: -5.18 (2SiCH<sub>3</sub>), 14.48 (CH<sub>3</sub>), 18.02 (CH<sub>2</sub>), 21.41 (CH<sub>3</sub>), 21.93 (CH<sub>3</sub>), 26.09 (CH<sub>2</sub>), 27.16 (tBu), 32.18 (C), 33.32 (CH<sub>3</sub>), 38.61 (C), 38.80 (CH<sub>2</sub>), 42.72 (C), 43.05 (CH<sub>2</sub>), 52.36 (CH), 63.38 (CH), 64.84 (C-12H<sub>2</sub>), 128.83 (C-7H), 157.16 (C-6), 199.44 (C=O).
- Van Rheeunen, V.; Kelly, R.C.; Cha D.Y. *Tetrahedron Letters*, **1976**, 1973-1976.
- Mori, K.; Tominaga, M.; Takigawa, T.; Matsui, M. *Synthesis*, **1973**, 790-791.
- Dess D.B.; Martin J.C. *J. Org. Chem.* **1983**, *48*, 4155-4156.
- Carbonate **20**:  $\text{C}_{21}\text{H}_{36}\text{O}_5$ ; MS CI:  $\text{MH}^+$  385, peaks at 367, 339, 295, 277, 251, 233; IR  $\text{cm}^{-1}$ : 3250 (OH), 1780 ( $\nu_{\text{C=O}}$ ), 1015, 1035, 1080 (C-O);  $^1\text{H}$  NMR, 250 MHz, one of the 1'-epimer,  $\delta$  ppm: 1.05 (3H, s, C-20H<sub>3</sub>), 1.10 (3H, s, C-19H<sub>3</sub>), 1.14 (3H, s, C-18H<sub>3</sub>), 1.19 (3H, t, J=7, CH<sub>2</sub>CH<sub>3</sub>), 1.33 (3H, d, J=5, CHCH<sub>3</sub>), 1.43 (3H, s, C-17H<sub>3</sub>), 0.9-1.90 (10 H, m, CH, CH<sub>2</sub>), 3.47 (2H, m, CH<sub>2</sub>CH<sub>3</sub>), 3.47 and 3.75 (2H, 2m, CH<sub>2</sub>-12), 4.58 (1H, d, J=7, H-7), 5.05 (1H, dd, J=4, J'=7, C-6H), 5.17 (1H, q, J=5, C-1'H).
- Synthetic **1**:  $\text{C}_{20}\text{H}_{34}\text{O}_3$ , HR CIMS ( $\text{CH}_4+\text{NH}_3$ )  $\text{MNH}_4^+$  calc. 341.2929 found 341.2890,  $\text{MH}^+$  calc. 323.2586 found 323.2572, UV  $\lambda_{\text{max}}$  EtOH: 231.8 nm ( $\epsilon$  18.000);  $^1\text{H}$  NMR, 250 MHz,  $\delta$  ppm: 1.0 (3H, s, C-18H<sub>3</sub>), 1.22 (6H, s, C-4 $\alpha$ H<sub>3</sub>, C-4 $\beta$ H<sub>3</sub>), 1.37 (3H, s, C-17H<sub>3</sub>), 1.81 (3H, s, C-16H<sub>3</sub>), 0.8-1.8 (8H, m, CH<sub>2</sub>), 2.29 and 2.49 (2H, ABXY, C-11H<sub>2</sub>), 3.43 (1H, d, J=4, C-7H), 4.43 (1H, broad t, C-6H), 4.93 (1H, d, J=9, C-15H), 5.08 (1H, d, J=18, C-15H), 5.60 (1H, broad t, J=6, C-12H), 6.35 (1H, dd, J=18, J'=9, C-14H);  $^{13}\text{C}$  NMR,  $\delta$  ppm: 11.96 (CH<sub>3</sub>), 16.80 (CH<sub>3</sub>), 18.77 (CH<sub>2</sub>), 19.52 (CH<sub>3</sub>), 23.41 (CH<sub>2</sub>), 24.02 (CH<sub>3</sub>), 33.45 (CH<sub>3</sub>), 34.08 (C), 39.76 (C), 42.25 (CH<sub>2</sub>), 43.74 (CH<sub>2</sub>), 55.77 (CH), 60.58 (CH), 70.93 (CH), 77.28 (C), 80.67 (CH), 110.73 (C-15H<sub>2</sub>), 133.0 (C-13), 135.60 (C-12H), 141.54 (C-14H).

(Received in France 18 June 1993; accepted 9 July 1993)